By Lin Hsin-han and William Hetherington / Staff reporter, with staff writerThe government would protect Taiwan’s traditional Chinese medicine industry and promote its expansion into international markets, President Tsai Ing-wen （蔡英文） said yesterday.
A Chinese medicine-based herbal formula developed in Taiwan called Taiwan Chingguan Erhau (清冠二號), or NRICM102, could reduce the mortality rate of COVID-19 cases who experience severe symptoms by 50 percent, National Research Institute of Chinese Medicine (NRICM) director Su Yi-chang (蘇奕彰) said.
Su talked about the treatment on Sunday at the Taipei Traditional Chinese Medicine International Forum, saying that following the success of Taiwan Chingguan Yihau (清冠一號), or NRICM101, the institute is applying for patents and trademarks for the new formulation.
In 2020, permission was granted to export Taiwan Chingguan Yihau, and it has been sold in more than 50 countries with
By Tsai Si-pei and Liu Tzu-hsuan / Staff reporter, with staff writerA Chinese medicine-based herbal formula developed in Taiwan called Taiwan Chingguan Erhau （清冠二號）, or NRICM102, could reduce the mortality rate of COVID-19 cases who experience severe symptoms by 50 percent, National Research Institute of Chinese Medicine （NRICM） director Su Yi-chang （蘇奕彰） said.
2021/05/27 13:57 Herbal supplement NRICM101 Herbal supplement NRICM101 (CNA photo) TAIPEI (Taiwan News) Taiwan-based Sun Ten Pharmaceutical Co. (順天堂) announced Wednesday (May 26) its donation to hospitals of the first batch of a herbal drug touted as being able to treat COVID-19. Developed by the National Research Institute of Chinese Medicine (NRICM) in 2020, the treatment NRICM101 (清冠一號) contains 10 herbs, including mint, Chinese skullcap, houttuynia, and licorice. The product has proven effective at inhibiting coronavirus replication and preventing the cytokine storm, in which the body attacks its own cells. It s said to be able to reduce the chance of severe illness in coronavirus patients without side effects, according to NRICM.